⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of PAION Pharma GmbH and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
PAION Pharma GmbH
↗Aachen, Germany
PAION Pharma GmbH is a specialty pharmaceutical company focused on the development and distribution of innovative medicines for anesthesia, intensive care, and critical care medicine. It operates as an independent subsidiary of the Humanwell Healthcare Group.
The company's portfolio includes remimazolam (Byfavo®), an ultra-short-acting benzodiazepine sedative/anesthetic, as well as intensive care products such as Angiotensin II (GIAPREZA®) and eravacycline (XERAVA®) in selected European markets.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Anesthesia and Critical Care
SIZE & FINANCIALS
Employees:1-50
Revenue:$10M-$20M
Founded:2000
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:Humanwell Healthcare Group
Acquired By:Humanwell Healthcare Group (2024-02-01)
Key Partnerships:Humanwell Healthcare Group (Parent), Viatris (Distribution partnership in Europe)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Tilmann Bur - Managing Director
Scientific Founders:Mariola Söhngen, Wolfgang Söhngen
LINKS
Website:paion.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with PAION Pharma GmbH. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.